Bristol-Myers Squibb Company (BMY)
-NYSE 46.40 
2.34(5.31%) 23 May 04:01 SGT|After Hours
:
46.55 0.15 (0.32%) 23 May 07:17 SGT
| Prev Close: | 44.06 |
|---|
| Open: | 44.99 |
|---|
| Bid: | 46.55 x 200 |
|---|
| Ask: | 46.65 x 100 |
|---|
| 1y Target Est: | 38.70 |
|---|
| Beta: | 0.12 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | 44.84 - 47.48 |
|---|
| 52wk Range: | 30.64 - 47.48 |
|---|
| Volume: | 25,347,565 |
|---|
| Avg Vol (3m): | 10,311,500 |
|---|
| Market Cap: | 76.21B |
|---|
| P/E (ttm): | 52.55 |
|---|
| EPS (ttm): | 0.88 |
|---|
| Div & Yield: | 1.40 (3.20%) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Most active New York Stock Exchange-traded stocksAP(Thu, 06:10 SGT)
- NYSE stocks posting largest percentage increasesAP(Thu, 06:08 SGT)
- Final Glance: Pharmaceuticals companiesAP(Thu, 06:08 SGT)
- Midday Glance: Pharmaceuticals companiesAP(Thu, 01:17 SGT)
- Early Glance: Pharmaceuticals companiesAP(Wed, 22 May)
- Ahead of the Bell: Analyst upgrades Bristol-MyersAP(Wed, 22 May)
- FDA OKs Bristol's HIV drug for younger patientsAP(Sat, 4 May)
- Sanofi earnings slashed in first quarterAP(Thu, 2 May)
- Earnings Preview: Merck to key on coming new drugsAP(Tue, 30 Apr)
- Earnings Preview: Pfizer to report Q1 resultsAP(Sat, 27 Apr)
- Bristol-Myers Inks OTC DealZacks(Thu, 14 Feb)
- MDCO-BMY Deal Comes into EffectZacks(Tue, 12 Feb)
- Vical's Loss Narrower than ExpectedZacks(Sat, 9 Feb)
- Generics Continue to Hurt SanofiZacks(Sat, 9 Feb)
- Pipeline Setback for IdenixZacks(Fri, 8 Feb)
Key Statistics
| Forward P/E (1 yr): | 21.78 |
|---|
| P/S (ttm): | 4.47 |
|---|
| Ex-Dividend Date: | 03-Apr-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.81 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.44 |
|---|
| Mean Recommendation*: | 2.5 |
|---|
| PEG Ratio (5 yr expected): | 2.58 |
|---|
Business Summary
Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide.
View More